Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. Review uri icon

Overview

abstract

  • Esophagogastric cancer is a worldwide health problem. The addition of the epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab to chemotherapy increased the overall survival of patients with metastatic HER2-positive esophagogastric cancer. This article discusses the available data to support HER2 as validated biomarker and recently completed and ongoing clinical trials of HER2-directed agents in metastatic and localized disease. Also reviewed is the mechanisms of resistance for HER2-directed therapy and ongoing research strategies including new imaging techniques and studies with patient-derived xenografts.

publication date

  • February 10, 2017

Research

keywords

  • Antineoplastic Agents
  • Breast Neoplasms
  • Molecular Targeted Therapy
  • Receptor, ErbB-2

Identity

Scopus Document Identifier

  • 85012028857

Digital Object Identifier (DOI)

  • 10.1016/j.soc.2016.10.005

PubMed ID

  • 28279471

Additional Document Info

volume

  • 26

issue

  • 2